Latham & Watkins Advises GSK on Strategic Alliance With Rgenta Therapeutics to Develop RNA-Targeted Small Molecule Splice Modulators

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA for oncology and neurological disorders, has announced that it has entered into a multi-year, multi-target strategic research alliance with GSK. The alliance aims to advance the discovery and development of novel RNA-targeted small molecule splice modulators for multiple disease areas including oncology.

Latham & Watkins LLP advised GSK in the transaction, with a healthcare and life sciences team led by New York partner Aaron Gardner, with associate Arun Mohan. Advice was also provided by Washington, D.C. partner Ian Conner and Bay Area partner Benjamin Potter, with associate Lauren Lockett.